Research chemicalResearch chemicalBenzodiazepine analogueDepressant

Difludiazepam

Also known as Difludiazepam · 2'-difluoro designer benzodiazepine

Written by enwyReviewed 4 Aug 20261 sources0 comments

Difludiazepam is a potent designer benzodiazepine bearing two fluorine substituents, sold as a research chemical. It produces the sedative, anxiolytic and amnestic effects of the class and is reported to be strong by weight. It has no clinical human characterisation; information is limited to analytical work and user reports.

01 Overview

Difludiazepam is a difluorinated benzodiazepine that emerged on the research-chemical market. It is typically found as powder, pellets or blotters and is potent per milligram, so small dosing errors are consequential. It has been scheduled in some jurisdictions as it appeared in seized designer-benzodiazepine products.

Reported effects are the familiar benzodiazepine set: sedation, anxiolysis, muscle relaxation and amnesia, with a duration in the medium-to-long range. As with other grey-market benzodiazepines, misdosing, blackouts and dependence are the dominant practical hazards. No clinical human data exist.

02 Mechanism

Positive allosteric modulation of GABA-A receptors at the benzodiazepine binding site.

03 Dosing

Tier	Dose	Route	Notes
Light	0.25–0.75 mg	Oral	Potent; volumetric dosing advised.
Common	0.75–1.5 mg	Oral	Redosing readily causes over-sedation and amnesia.

04 Effects

Effect	Magnitude	Evidence
AnxiolysisReduction of anxiety consistent with the class.	Marked	Anecdotal
SedationDrowsiness and reduced arousal.	Strong	Anecdotal
Muscle relaxationReduced muscle tension.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Dependence and withdrawalTolerance and dependence develop with regular use; abrupt cessation risks seizures.	Severe	Common with regular use	Anecdotal
Blackouts and amnesiaAnterograde amnesia and blackouts, worsened by alcohol.	Moderate	Common at higher doses	Anecdotal
Additive respiratory depressionDangerous with opioids or alcohol.	Life-threatening	With CNS depressants	Observational

06 Legal status

United States

Not federally scheduled

as of Jan 2026

Controlled substance

as of Jan 2026

07 References

Identification of difludiazepam in seized materialsDrug Testing and Analysis

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.